M&T Bank
EGRX

M&T Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

M&T Bank’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,112
Closed -$526K – 1860
2015
Q3 		$526K Buy
+7,112
New +$592K ﹤0.01% 1046

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

M&T Bank's EGRX Position: Q4 2015 in Review

M&T Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2015, closing a stake of 7,112 shares — an estimated $526K sold.

M&T Bank first reported a position in EGRX in Q3 2015 and held it in 1 quarter. The position peaked at $526K in Q3 2015. 133 funds tracked by Wall St. Rank hold EGRX as of Q4 2015.

  • M&T Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • M&T Bank sold 7,112 Eagle Pharmaceuticals, Inc. shares in Q4 2015, an estimated $526K.
  • M&T Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • M&T Bank's Eagle Pharmaceuticals, Inc. position peaked at $526K in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2015.

Based on M&T Bank's 13F filing for Q4 2015, filed 12 Feb 2016.